Nanomedicine Journal, published by Mashhad University of Medical Sciences, serves as a vital platform for research and developments in the dynamic field of nanotechnology applied to medicine. With an ISSN of 2322-3049 and an E-ISSN of 2322-5904, this Open Access journal, operational since 2013, makes cutting-edge research freely accessible to encourage collaborative efforts in this rapidly evolving domain. The journal navigates various areas, including bioengineering, biomedical engineering, materials science, and pharmacology, holding prestigious rankings in categories relevant to these fields. The 2023 Scopus Rankings reveal its significant standing within the scientific community, particularly with a 76th percentile in general medicine. By bridging the gap between laboratory technologies and clinical applications, the Nanomedicine Journal aims to empower researchers, professionals, and students alike to contribute to the innovative landscape of nanomedicine. With a convergence period extending from 2019 to 2024 and an established reputation, this journal is essential for those pursuing advancements in therapeutic solutions and diagnostics through nanotechnology.

Acta Neuropathologica Communications is a distinguished open-access journal published by BMC since 2013, focusing on the rapidly advancing fields of neurology, cellular and molecular neuroscience, and pathology. Located in the United Kingdom, this journal serves as a vital platform for researchers to disseminate significant findings that enhance our understanding of neurological disorders and their underlying mechanisms. With an impressive impact factor reflected in its Q1 ranking across multiple relevant categories, including Cellular and Molecular Neuroscience, Neurology (Clinical), and Pathology and Forensic Medicine, Acta Neuropathologica Communications stands out in the academic community for its rigorous peer-review process and commitment to high-quality research. The journal’s Scopus rankings highlight its global relevance, placing it in the top percentiles among leading research publications. Researchers, professionals, and students alike are encouraged to access and contribute to this essential resource, fostering a collaborative and informed approach to tackling the complexities of neuropathology and neuroscience.

TRENDS IN NEUROSCIENCES, published by CELL PRESS, is a leading journal in the field of neuroscience, offering cutting-edge insights and important developments in the rapidly evolving landscape of brain research. With an impressive Impact Factor and ranking in the top quartile (Q1) of the category for Neuroscience (miscellaneous), it is positioned as a vital resource for researchers and professionals seeking to stay abreast of the latest discoveries and trends from 1978 to the present. Specifically ranked #3 out of 113 in General Neuroscience by Scopus, this journal promotes the interdisciplinary exchange of ideas and knowledge, making it an essential platform for students and experienced scholars alike. Although it is not an Open Access journal, its value lies in its rigorous peer-review process and commitment to maintaining the highest standards of academic integrity. By continuing to explore the complexities of neural processes and behavior, TRENDS IN NEUROSCIENCES plays a crucial role in shaping the future of neuroscience research and education.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

NEUROLOGICAL RESEARCH, published by TAYLOR & FRANCIS LTD, is a distinguished journal focusing on the diverse and evolving field of neurology. Established in 1979, this journal has been a prominent platform for disseminating groundbreaking research and clinical advances up to 2024. With an ISSN of 0161-6412 and an E-ISSN of 1743-1328, it offers valuable insights for researchers, professionals, and students interested in the intricate workings of the nervous system. The journal holds a respectable Q2 ranking in the field of Medicine (miscellaneous) and Q3 in the categories of Neurology and Clinical Neurology, reflecting its commitment to high-quality research. Although NEUROLOGICAL RESEARCH does not currently offer an open access option, its contributions to the literature are vital for fostering advancements in neurological understanding and treatment. With an engaged readership and a mission to advance scientific knowledge, NEUROLOGICAL RESEARCH serves as a crucial resource for anyone dedicated to neurological health and innovation.

The Journal of Neuroimmune Pharmacology, published by Springer, is a premier academic journal dedicated to advancing the field of pharmacology intersecting with neuroscience and immunology. With an outstanding impact factor and proudly positioned in the Q1 quartile across multiple categories, this journal showcases cutting-edge research that enhances our understanding of the neuroimmune system and its pharmacological implications. Established in 2006 and continuing through 2024, it serves as a vital resource for researchers, professionals, and students alike, offering insights into the mechanisms of drug action, disease processes, and therapeutic strategies. As a testament to its excellence, the journal ranks prominently in Scopus metrics within its discipline, making it an essential platform for disseminating high-quality research that drives innovation in immunology, allergy, neuroscience, and pharmacology.

Neurology-Neuroimmunology & Neuroinflammation, published by LIPPINCOTT WILLIAMS & WILKINS, stands at the forefront of research in the rapidly evolving fields of neurology and neuroimmunology. Since its inception in 2014, this prestigious journal has embraced an Open Access model, ensuring that groundbreaking findings are readily available to researchers, clinicians, and students worldwide. Covering a broad spectrum of topics related to neuroinflammation, the journal has gained a remarkable reputation, attaining a Q1 ranking in both Neurology and Neurology (clinical) as of 2023, and ranking #6 out of 192 in the neuroscience category on Scopus. The journal's commitment to high-quality research aims to facilitate the understanding of neurological disorders, promote innovative therapies, and inspire collaboration among professionals. Addressing critical issues at the intersection of neurology, immunology, and clinical practice, Neurology-Neuroimmunology & Neuroinflammation is an essential platform for the dissemination of knowledge and the advancement of this vital field.

CELLULAR AND MOLECULAR NEUROBIOLOGY, published by SPRINGER/PLENUM PUBLISHERS, stands as a significant contributor to the fields of cell biology and neuroscience, holding a distinguished position in the academic community with an impact factor that places it in the Q2 category for both Cell Biology and Cellular and Molecular Neuroscience, along with Q1 in Medicine (miscellaneous). Since its inception in 1981, this journal has provided a critical platform for innovative research and thought-provoking reviews, fostering a deeper understanding of complex neurobiological mechanisms. The journal’s rigorous peer-review process ensures the publication of high-quality manuscripts that offer valuable insights into cellular processes and neural functions. With a commitment to advancing knowledge and promoting collaboration among researchers, CELLULAR AND MOLECULAR NEUROBIOLOGY remains an essential resource for professionals and students alike, looking to stay updated on the latest developments in neurobiology.

CNS & Neurological Disorders-Drug Targets is a distinguished journal that focuses on contemporary research and advancements in the realms of neurology, pharmacology, and drug development. Published by Bentham Science Publishers, this journal serves as an essential platform for researchers, professionals, and students interested in the intricate workings of the central nervous system and the evolving strategies to target neurological disorders through pharmacological innovations. With a robust impact factor reflecting its academic relevance, CNS & Neurological Disorders-Drug Targets is categorized in the Q2 quartile for both Medicine (miscellaneous) and Pharmacology, and Q3 for Neuroscience in the 2023 rankings. The journal's Scopus rankings further reinforce its authority, positioning it within the top half of its categories. Operating out of the United Arab Emirates, the journal has been a loyal contributor to the scientific discourse since its inception in 2006 and will continue until at least 2024, ensuring a dynamic channel for the latest findings and reviews in this vital field. As an open-access publication, it prioritizes accessibility, thus fostering a wider impact among scholars and practitioners alike, making it a valuable resource for all stakeholders in neurological and pharmacological research.

ACTA NEUROPATHOLOGICA, published by Springer, is a leading journal in the fields of cellular and molecular neuroscience, clinical neurology, and pathology, recognized for its exceptional quality and impactful research. With an impressive impact factor and currently ranked in the Q1 tier across multiple categories in 2023, this journal serves as a premier platform for the dissemination of groundbreaking findings in neuropathology. The journal's robust Scopus rankings highlight its influence, standing at #2 in Pathology and Forensic Medicine and #5 in Clinical Neurology. Since its inception in 1961, ACTA NEUROPATHOLOGICA has provided crucial insights into neurological diseases and disorders, contributing significantly to the advancement of medical science. Aimed at researchers, practitioners, and students alike, this journal fosters a deeper understanding of neurological conditions and encourages innovative approaches within the field. It is essential reading for anyone dedicated to unraveling the complexities of the nervous system.